Adjuvant CDK4/6 Inhibitors in Hormone Receptor-positive Early Breast Cancer: One Fits All?

Overview

Journal Transl Breast Cancer Res

Publisher AME Publishing Company

Date 2024 Nov 13

PMID 39534583

Authors

Caterina Gianni

Eleonora Nicolo

Massimo Cristofanilli

Affiliations

Soon will be listed here.

References

Gnant M, Dueck A, Frantal S, Martin M, Burstein H, Greil R . Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2021; 40(3):282-293. PMC: 10476784. DOI: 10.1200/JCO.21.02554. View

Rastogi P, OShaughnessy J, Martin M, Boyle F, Cortes J, Rugo H . Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year.... J Clin Oncol. 2024; 42(9):987-993. PMC: 10950161. DOI: 10.1200/JCO.23.01994. View

Lee K, Lord S, Finn R, Lim E, Martin A, Loi S . The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat. 2018; 174(1):271-278. DOI: 10.1007/s10549-018-5054-x. View

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts R . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015; 7(302):302ra133. DOI: 10.1126/scitranslmed.aab0021. View

Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D . Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024; 390(12):1080-1091. DOI: 10.1056/NEJMoa2305488. View

Wander S, Cohen O, Gong X, Johnson G, Buendia-Buendia J, Lloyd M . The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020; 10(8):1174-1193. PMC: 8815415. DOI: 10.1158/2159-8290.CD-19-1390. View

Noone A, Cronin K, Altekruse S, Howlader N, Lewis D, Petkov V . Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev. 2016; 26(4):632-641. PMC: 5380602. DOI: 10.1158/1055-9965.EPI-16-0520. View

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P . 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017; 377(19):1836-1846. PMC: 5734609. DOI: 10.1056/NEJMoa1701830. View

Loibl S, Marme F, Martin M, Untch M, Bonnefoi H, Kim S . Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021; 39(14):1518-1530. DOI: 10.1200/JCO.20.03639. View

10.

Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L . Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. Cancers (Basel). 2022; 14(8). PMC: 9029479. DOI: 10.3390/cancers14081898. View

11.

Morrison L, Loibl S, Turner N . The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2023; 21(2):89-105. DOI: 10.1038/s41571-023-00840-4. View

12.

Lloyd M, Spring L, Bardia A, Wander S . Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2021; 28(5):821-830. DOI: 10.1158/1078-0432.CCR-21-2947. View

13.

Johnston S, Toi M, OShaughnessy J, Rastogi P, Campone M, Neven P . Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2022; 24(1):77-90. PMC: 11200328. DOI: 10.1016/S1470-2045(22)00694-5. View

14.

Mittal A, Valiente C, Tamimi F, Schlam I, Sammons S, Tolaney S . Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. Cancers (Basel). 2023; 15(7). PMC: 10093251. DOI: 10.3390/cancers15072015. View

15.

Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte J, Ignatiadis M . How I treat endocrine-dependent metastatic breast cancer. ESMO Open. 2023; 8(2):100882. PMC: 9969253. DOI: 10.1016/j.esmoop.2023.100882. View

16.

Pala L, Conforti F, Goldhirsch A . Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy. Lancet Oncol. 2020; 21(3):e130. DOI: 10.1016/S1470-2045(20)30072-3. View

17.

Burris H, Chan A, Bardia A, Beck J, Sohn J, Neven P . Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer. 2021; 125(5):679-686. PMC: 8405616. DOI: 10.1038/s41416-021-01415-9. View